Noninfectious anterior uveitis:
An inflammatory disease of the eye.
Uveitis, in its various forms, is estimated to be responsible for 10% of the blindness in the United States. Anterior uveitis, which occurs in the front of the eye, is the most common form, predominantly occurring in young and middle-aged people.
Our focus at Aldeyra is on noninfectious anterior uveitis, a severe inflammatory ocular disease. Often occurring in conjunction with other autoimmune diseases, it is characterized by pain, sensitivity to light, redness, loss of vision, and other ocular symptoms.
Importantly, uveitis can be considered a model of inflammation. If a drug shows signs of efficacy in uveitis, it may also be efficacious in many other inflammatory diseases.
Current noninfectious anterior uveitis treatment challenges.
Up to now, noninfectious anterior uveitis has typically been treated with topical corticosteroids. However, prolonged use of corticosteroids increases the incidence of cataracts and glaucoma in uveitis. It may also increase the incidence of ocular infection, corneal ulceration, and other toxicities.
The treatment potential of Reproxalap.
Non-infectious anterior uveitis is characterized in part by elevated levels of Reactive aldehyde species (RASP). Reproxalap, Aldeyra’s lead compound, has the potential to mitigate inflammation in NAU by sequestering RASP.
The prevalence of noninfectious anterior uveitis.
In the United States alone, noninfectious anterior uveitis affects about 260,000 patients annually. Patients with recurrent episodes often develop cataracts, while severe cases may lead to glaucoma and retinal dysfunction.
NONINFECTIOUS ANTERIOR UVEITIS
We have previously announced positive results from our Phase 2 clinical trial of reproxalap ophthalmic solution. In April 2019 we announced that the last patient completed dosing in the Phase 3 SOLACE trial. SOLACE is a randomized, multicenter, double-masked, parallel-group, vehicle-controlled Phase 3 clinical trial of 0.5% topical ocular reproxalap in patients with NAU. The primary outcome measure is time-to-cure without rescue therapy. and started enrollment for Phase 3 in patients with noninfectious anterior uveitis.